InferRead DR Tuberculosis
Infervision| Product specifications |
Information source:
Public
Last updated: Sept. 1, 2021 |
| General | |
|---|---|
| Product name | InferRead DR Tuberculosis |
| Company | Infervision |
| Subspeciality | Chest |
| Modality | X-ray |
| Disease targeted | Tuberculosis |
| Key-features | Tuberculosis detection |
| Suggested use | |
| Data characteristics | |
| Population | |
| Input | |
| Input format | |
| Output | |
| Output format | |
| Technology | |
| Integration | |
| Deployment | |
| Trigger for analysis | |
| Processing time | |
| Certification | |
|
CE
|
Certified,
Class IIa
, MDD
|
|
FDA
|
No or not yet |
| Market presence | |
| On market since | 01-2020 |
| Distribution channels | Stop TB Partnership Global Drug Facility |
| Countries present (clinical, non-research use) | |
| Paying clinical customers (institutes) | |
| Research/test users (institutes) | |
| Pricing | |
| Pricing model | |
| Based on | |
| Evidence | |
| Peer reviewed papers on performance |
|
| Non-peer reviewed papers on performance | |
| Other relevant papers | |